| ID | 115865 |
| 著者 | |
| キーワード | sodium-glucose co-transporter-2 inhibitors (SGLT2i)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection trial (DAPA-HF) Empagliflozin outcome trial in Patients with chronic heart Failure with Reduced Ejection Fraction trial (EMPEROR-Reduced)
dapagliflozin-chronic kidney disease trial (DAPA-CKD)
the evaluation of Ertugliflozin efficacy and Safety Cardiovascular outcomes trial (VERTIS-CV)
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Recently, sodium-glucose co-transporter-2 inhibitors (SGLT2i) have been a topic for oral hypoglycemic agents (OHAs) for diabetes. It suggested positive effects on the heart and kidneys from EMPAREG-OUTCOME study, CANVAS program, and DECLARE-TIMI 58 study. SGLT2i are expected to become the useful agents that transcend OHAs, from three recent reports. They are i) Dapagliflozin in Patients with Heart Failure and Reduced Ejection trial (DAPA-HF), ii) the Empagliflozin outcome trial in Patients with chronic heart Failure with Reduced Ejection Fraction trial (EMPEROR-Reduced), and iii) dapagliflozin-chronic kidney disease trial (DAPA-CKD). SGLT2i may become an agent for late-aging and longevity in the future.
|
| 掲載誌名 |
Recent Research in Endocrinology and Metabolic Disorder
|
| ISSN | 27175138
|
| 巻 | 3
|
| 号 | 1
|
| 開始ページ | 27
|
| 終了ページ | 30
|
| 発行日 | 2021-03-27
|
| 権利情報 | This open access article is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). http://creativecommons.org/licenses/by/4.0
|
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
